Abstract

The workshop held in the Netherlands from October 20–22, 2023, united 27 scientists from academia, healthcare, and industry representing 11 countries, alongside four patient and charity representatives. Focused on Kennedy's Disease (KD), also known as spinal and bulbar muscular atrophy (SBMA), the workshop aimed to consolidate knowledge, align on clinical trial designs, and promote participative medicine for effective treatments. Discussions emphasized KD's molecular mechanisms, highlighting its status as a neuromuscular disorder with motor neuron degeneration. Strategies for therapeutic intervention, including AR activity modulation and targeting post-translational modifications, were proposed. The need for diagnostic, prognostic, and target engagement biomarkers was stressed. Challenges in patient stratification and clinical trial recruitment were acknowledged, with the International KD/SBMA Registry praised for its role. The workshop concluded with a patient-focused session, underscoring challenges in KD diagnosis and the vital support provided by patient associations.

Original languageEnglish
Pages (from-to)8-19
Number of pages12
JournalNeuromuscular Disorders
Volume38
DOIs
StatePublished - May 2024

Funding

FundersFunder number
Muscular Dystrophy UK
Stiftung für die Erforschung der Muskelkrankheiten
Prinses Beatrix Spierfonds
Muskelsvindfonden
Association Française contre les Myopathies
Spierziekten Nederland
Deutsche Gesellschaft für Muskelkranke
European Neuromuscular Centre
Fondazione Telethon

    Keywords

    • Androgen receptor
    • Clinical trials
    • ENMC
    • Kennedy disease
    • Patient registry
    • SBMA

    Fingerprint

    Dive into the research topics of '271st ENMC international workshop: Towards a unifying effort to fight Kennedy's disease. 20-22 October 2023, Hoofddorp, Netherlands'. Together they form a unique fingerprint.

    Cite this